## Note
nid: 1495599255138
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Pembrolizumab, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions::Pembrolizumab, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::Cancer_Immunotherapy, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::2-RelativelyHighYield
markdown: false

### Text
<div>
  <div>
    The <b>PD1</b> receptor is normally involved in the maintenance
    of {{c1::<b style="font-weight: normal;">peripheral</b>}}
    <b>immunologic</b> <span style=
    "font-weight: normal;"><b>tolerance</b></span>
  </div>
</div>

### Extra
<div>
  This "checkpoint" system is another line of defense against
  autoreactive immune cells that have escaped <u>central
  tolerance</u> (ex. CTLA4)
</div>
<div><img src="paste-71588514889729.jpg"></div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy
#REF!

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_7.png"></a>
</div>

### Additional Resources


### One by one

